New blood thinning agent approved for GPs in Scotland

Rivaroxaban for DVT and for stroke prevention in AF has been approved by the Scottish Medicines Consortium (SMC), widening treatment options for GPs in Scotland.

DVT: The thrombus (abnormal clot, white) is blocking the flow of blood (red) in the vein (Photograph: SPL)
DVT: The thrombus (abnormal clot, white) is blocking the flow of blood (red) in the vein (Photograph: SPL)

Marketed as Xarelto by Bayer and licenced in the UK, rivaroxaban works by blocking Factor Xa, a blood clotting agent.

The SMC accepted rivaroxaban for the treatment for DVT and prevention of recurrent DVT and pulmonary embolism following acute DVT in adults.

It also accepted the anticoagulant for limited use in the prevention of stroke and systemic embolism in adults with non-valvular AF and at least one risk factor. Use is restricted to patients who have poor INR control despite compliance with coumarin anticoagulant, and to patients who are allergic to or unable to tolerate coumarin anticoagulants.

Evidence considered by the consortium found rivaroxaban worked as well as standard therapy, but showed additional bleeding against placebo. SMC said it approved the drug because it offers 'value for money'.

The drug was previously accepted by SMC for prevention of venous thromboembolism in adults who undergo hip and knee surgery in 2008.

NICE is also considering rivaroxaban for preventing stroke and systemic embolism in AF. But it held back from recommending the drug in draft guidance issued in January.

The institute said the relative effectiveness of rivaroxaban compared with warfarin had been 'overestimated' for the UK population, and called on Bayer to submit further evidence.

NICE will issue its final guidance by May.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Locum GP exodus to salaried roles as COVID-19 pandemic hits income

Locum GP exodus to salaried roles as COVID-19 pandemic hits income

As many as 1,000 GPs may have quit locum work to take up salaried positions since...

Flexibility over PCN recruitment cash extended in bid to boost staff this year

Flexibility over PCN recruitment cash extended in bid to boost staff this year

NHS chiefs have added 'nurse associates' to the list of roles PCNs can hire this...

Fellowship scheme offers £10,000 a year to support every new GP

Fellowship scheme offers £10,000 a year to support every new GP

A two-year GP fellowship scheme promised in the 2020/21 GP contract deal will offer...

NHS chiefs warned not to underestimate pressure on GPs as figures show sharp rise in workload

NHS chiefs warned not to underestimate pressure on GPs as figures show sharp rise in workload

GP workload has surged sharply in recent months, official data show, underscoring...

Call for 'decisive action' to halt decline in GP continuity of care

Call for 'decisive action' to halt decline in GP continuity of care

Researchers have called for 'decisive action' to reverse declining continuity of...

Salaried roles now the most attractive career option for GPs, poll reveals

Salaried roles now the most attractive career option for GPs, poll reveals

Salaried jobs are now the most attractive career option for GPs, according to a GPonline...